---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-074005"
form_type: "8-K"
ticker: "SENS"
cik: "0001616543"
company_name: "Senseonics Holdings, Inc."
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T02:51:31.086756+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Senseonics sees H1 2024 net rev $10M, +21% YoY; FY 2024 guidance $22-24M

## Summary
- Reaffirmed H1 2024 global net revenue $10M, 21% growth over H1 2023.
- US new patient starts H1 2024 >200% higher than H1 2023.
- FDA 510(k) for 365-day Eversense on track for Q4 2024 launch.
- Mercy Health collaboration initiated; first insertions targeted Q3 2024.
- FY 2024 revenue guidance $22-24M; cash utilization ~$70M.

## SEC filing metadata
- accession: 0001104659-24-074005
- form_type: 8-K
- ticker: SENS
- cik: 0001616543
- company_name: Senseonics Holdings, Inc.
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1616543/000110465924074005/0001104659-24-074005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1616543/000110465924074005/tm2417819d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-074005
- JSON: https://secwatch.observer/filing/0001104659-24-074005.json
- Plain text: https://secwatch.observer/filing/0001104659-24-074005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.